Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191,678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.
Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, Ambrogio C, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Jänne PA. Köhler J, et al. Among authors: li j. Mol Cancer Ther. 2021 Apr;20(4):641-654. doi: 10.1158/1535-7163.MCT-20-0531. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536188 Free PMC article.
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA. Ambrogio C, et al. Among authors: li s, li j. Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11. Cell. 2018. PMID: 29336889 Free article.
Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer.
Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Jänne PA, Oxnard GR. Cooper AJ, et al. Among authors: li j. Clin Cancer Res. 2020 Aug 1;26(15):4072-4079. doi: 10.1158/1078-0432.CCR-20-0397. Epub 2020 Apr 20. Clin Cancer Res. 2020. PMID: 32312893 Free PMC article. Clinical Trial.
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, Redig AJ, Köhler J, Dholakia KH, Chen Y, Richard E, Nokin MJ, Santamaria D, Gokhale PC, Awad MM, Jänne PA, Ambrogio C. Ricciuti B, et al. Among authors: li j. Clin Cancer Res. 2022 Apr 14;28(8):1640-1650. doi: 10.1158/1078-0432.CCR-21-2719. Clin Cancer Res. 2022. PMID: 35091439 Free PMC article.
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Kobayashi Y, et al. Among authors: li j. Nature. 2022 Mar;603(7900):335-342. doi: 10.1038/s41586-022-04451-4. Epub 2022 Mar 2. Nature. 2022. PMID: 35236983
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.
Kobayashi Y, Oxnard GR, Cohen EF, Mahadevan NR, Alessi JV, Hung YP, Bertram AA, Heppner DE, Ribeiro MF, Sacardo KP, Saddi R, Macedo MP, Blasco RB, Li J, Kurppa KJ, Nguyen T, Voligny E, Ananda G, Chiarle R, Katz A, Tolstorukov MY, Sholl LM, Jänne PA. Kobayashi Y, et al. Among authors: li j. Nat Commun. 2022 Sep 24;13(1):5614. doi: 10.1038/s41467-022-33210-2. Nat Commun. 2022. PMID: 36153311 Free PMC article.
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality.
Li Z, Jiang J, Ficarro SB, Beyett TS, To C, Tavares I, Zhu Y, Li J, Eck MJ, Jänne PA, Marto JA, Zhang T, Che J, Gray NS. Li Z, et al. Among authors: li j. ACS Cent Sci. 2024 Feb 26;10(6):1156-1166. doi: 10.1021/acscentsci.3c01245. eCollection 2024 Jun 26. ACS Cent Sci. 2024. PMID: 38947214 Free PMC article.
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer.
Plumber SA, Tate T, Al-Ahmadie H, Chen X, Choi W, Basar M, Lu C, Viny A, Batourina E, Li J, Gretarsson K, Alija B, Molotkov A, Wiessner G, Lee BHL, McKiernan J, McConkey DJ, Dinney C, Czerniak B, Mendelsohn CL. Plumber SA, et al. Among authors: li j. Nat Commun. 2024 Aug 2;15(1):6538. doi: 10.1038/s41467-024-50678-2. Nat Commun. 2024. PMID: 39095358 Free PMC article.
191,678 results
You have reached the last available page of results. Please see the User Guide for more information.